Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Skin Lesion Classification Using Densely Connected Convolutional Networks with Attention Residual Learning
57
Zitationen
5
Autoren
2020
Jahr
Abstract
Skin lesion classification is an effective approach aided by computer vision for the diagnosis of skin cancer. Though deep learning models presented advantages over traditional methods and brought tremendous breakthroughs, a precise diagnosis is still challenging because of the intra-class variation and inter-class similarity caused by the diversity of imaging methods and clinicopathology. In this paper, we propose a densely connected convolutional network with an attention and residual learning (ARDT-DenseNet) method for skin lesion classification. Each ARDT block consists of dense blocks, transition blocks and attention and residual modules. Compared to a residual network with the same number of convolutional layers, the size of the parameters of the densely connected network proposed in this paper has been reduced by half, while the accuracy of skin lesion classification is preserved. Our improved densely connected network adds an attention mechanism and residual learning after each dense block and transition block without introducing additional parameters. We evaluate the ARDT-DenseNet model with the ISIC 2016 and ISIC 2017 datasets. Our method achieves an ACC of 85.7% and an AUC of 83.7% in skin lesion classification with ISIC 2016 and an average AUC of 91.8% in skin lesion classification with ISIC 2017. The experimental results show that the method proposed in this paper has achieved a significant improvement in skin lesion classification, which is superior to that of the state-of-the-art method.
Ähnliche Arbeiten
Dermatologist-level classification of skin cancer with deep neural networks
2017 · 13.439 Zit.
Tumor Angiogenesis: Therapeutic Implications
1971 · 10.108 Zit.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
2011 · 7.668 Zit.
Pembrolizumab versus Ipilimumab in Advanced Melanoma
2015 · 5.804 Zit.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2017 · 5.355 Zit.